Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label MGY825 study in advanced non-small cell lung cancer
jRCT2031220278Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of MGY825 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Frequency of dose interruptions and reductions and 2 more. Started Oct 2022; status: completed.
02
Drugs
MGY825
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220278.